Endonovo Therapeutics, Inc.
ENDV · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $10 | $140 | $135 | $73 |
| % Growth | -92.8% | 3.6% | 85.2% | – |
| Cost of Goods Sold | $625 | $655 | $10 | $15 |
| Gross Profit | -$615 | -$515 | $125 | $58 |
| % Margin | -6,125.6% | -366.9% | 92.6% | 79.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $945 | $2,405 | $2,743 | $1,636 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $647 | $648 |
| Operating Expenses | $945 | $2,405 | $3,390 | $2,285 |
| Operating Income | -$1,560 | -$2,919 | -$3,264 | -$2,227 |
| % Margin | -15,532.5% | -2,081.7% | -2,411.7% | -3,045.7% |
| Other Income/Exp. Net | -$1,237 | $9,844 | -$15,210 | -$878 |
| Pre-Tax Income | -$2,797 | $6,925 | -$18,475 | -$3,105 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,797 | $6,925 | -$18,475 | -$3,105 |
| % Margin | -27,853.2% | 4,937.6% | -13,649.2% | -4,247.2% |
| EPS | -0.005 | 0.025 | -0.13 | -0.052 |
| % Growth | -120.3% | 119.3% | -150.5% | – |
| EPS Diluted | -0.005 | 0.005 | -0.13 | -0.052 |
| Weighted Avg Shares Out | 543,871 | 276,355 | 139,207 | 59,837 |
| Weighted Avg Shares Out Dil | 543,871 | 1,350,768 | 139,207 | 59,837 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1,237 | $1,282 | $1,322 | $942 |
| Depreciation & Amortization | $619 | $647 | $647 | $648 |
| EBITDA | -$941 | $8,854 | -$16,506 | -$1,515 |
| % Margin | -9,373.7% | 6,313.2% | -12,194.9% | -2,072.1% |